G/P方案用药中断或依从性欠佳仍维持高持续病毒学应答率
该事后分析汇总10项三期试验中2149例初治HCV患者,评估glecaprevir/pibrentasvir(G/P)8或12周方案的依从性。总体平均依从性99.4%,随治疗延长而下降;改良ITT人群SVR12达99.3%,非依从者仍维持较高SVR12。中断分析2902例中33例(1.1%)中断≥1天,SVR12率93.9%,无病毒学失败。
要点
- G/P总体平均依从性99.4%,随治疗周数延长依从性逐步下降
- 改良ITT人群SVR12为99.3%,非依从者SVR12仍较高
- 中断≥1天者SVR12率93.9%,无病毒学失败
核心结论
- G/P方案在用药中断或依从性欠佳患者中仍维持高SVR12率,支持直接抗病毒药物的「治疗宽容」概念。
研究设计与样本
- 依从性分析汇总10项三期临床试验的初治HCV基因1-6型无肝硬化或代偿期肝硬化患者。
- 中断分析汇总13项三期临床试验的全部HCV患者。
- 依从性基于药片计数评估,疗效指标为治疗后第12周持续病毒学应答(SVR12)。
主要发现
- 2149例患者总体平均依从性为99.4%。
- 依从性随治疗时长下降:第0-4周100%,第5-8周98.3%,第9-12周97.1%。
- ITT人群SVR12率为97.7%,改良ITT人群SVR12率为99.3%。
- 改良ITT人群中非依从者SVR12仍高:依从性<90%者为94.4%-100%,<80%者为83.3%-100%。
- 中断分析2902例中33例(1.1%)G/P中断≥1天,SVR12率为93.9%(31/33),无病毒学失败。
关键数值与推荐
- 依从性<90%的改良ITT患者SVR12范围为94.4%-100%。
- 依从性<80%的改良ITT患者SVR12范围为83.3%-100%。
- 治疗中断≥1天者SVR12率为93.9%(31/33)。
临床怎么用
- G/P方案疗效对轻度依从性下降和短期中断具有一定宽容度。
- 精神疾病与依从性<80%相关,较短疗程与依从性≥80%相关。
- 临床可据此对偶发漏服或短期中断患者减少不必要的停药或换药顾虑。
局限性
- 依从性分析基于药片计数,可能高估实际服药情况。
- 中断分析中中断事件数量较少(33例),结果解释需谨慎。
- 为事后分析,非预设终点,可能存在混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pangenotypic, all-oral direct-acting antivirals, such as glecaprevir/pibrentasvir (G/P), are recommended for treatment of hepatitis C virus (HCV) infection. Concerns exist about the impact on efficacy in patients with suboptimal adherence, particularly with shorter treatment durations. These post hoc analyses evaluated adherence (based on pill count) in patients prescribed 8- or 12-week G/P, the impact of nonadherence on sustained virologic response at post-treatment week 12 (SVR12), factors associated with nonadherence, and efficacy in patients interrupting G/P treatment. METHODS: Data were pooled from 10 phase 3 clinical trials of treatment-naive patients with HCV genotype 1-6 without cirrhosis/with compensated cirrhosis (treatment adherence analysis) and 13 phase 3 clinical trials of all patients with HCV (interruption analysis). RESULTS: Among 2,149 patients included, overall mean adherence was 99.4%. Over the treatment duration, adherence decreased (weeks 0-4: 100%; weeks 5-8: 98.3%; and weeks 9-12: 97.1%) and the percentage of patients with ≥80% or ≥90% adherence declined. SVR12 rate in the intention-to-treat (ITT) population was 97.7% (modified ITT SVR12 99.3%) and remained high in nonadherent patients in the modified ITT population (<90%: 94.4%-100%; <80%: 83.3%-100%). Psychiatric disorders were associated with <80% adherence, and shorter treatment duration was associated with ≥80% adherence. Among 2,902 patients in the interruption analysis, 33 (1.1%) had a G/P treatment interruption of ≥1 day, with an SVR12 rate of 93.9% (31/33). No virologic failures occurred. DISCUSSION: These findings support the impact of treatment duration on adherence rates and further reinforce the concept of "treatment forgiveness" with direct-acting antivirals.
引用
- Zamor PJ, Brown A, Dylla DE, et al. High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. Am J Gastroenterol. 2021. PMID: 34465693. doi:10.14309/ajg.0000000000001332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。